Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Treatment of Osteoarthritis with a Once‐Daily Dosing Regimen of Celecoxib: A Randomized, Controlled Trial
- Gary W. Williams, R. Ettlinger, +5 authors S. Geis
- Journal of clinical rheumatology : practical…
- 1 April 2000
No difference in efficacy or safety can be discerned between celecoxib 100 mg b.i.d. and 200 mg q.d., providing flexibility to both patients and physicians in choosing a dosing regimen. Expand
AJC Editor's consensus: Selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk.
Real-Time Intracellular Ca2+ Mobilization by Travoprost Acid, Bimatoprost, Unoprostone, and Other Analogs via Endogenous Mouse, Rat, and Cloned Human FP Prostaglandin Receptors
- C. Kelly, Gary W. Williams, N. Sharif
- Medicine, Chemistry
- Journal of Pharmacology and Experimental…
- 1 January 2003
It is demonstrated that bimatoprost, unoprostone, and bim atoprost acid possess direct agonist activities at the rat, mouse, and human FP prostanoid receptor and that travobrost acid is the most potent of the synthetic FP prostaglandin analogs tested. Expand
Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
Celecoxib 200mg/day and rofecoxib 25 mg/day are equally efficacious in treating the signs and symptoms of OA. Expand
Increased autophagy in CD4+ T cells of rheumatoid arthritis patients results in T‐cell hyperactivation and apoptosis resistance
- J. Loosdregt, M. Rossetti, +8 authors S. Albani
- Biology, Medicine
- European journal of immunology
- 1 December 2016
It is demonstrated that the rate of autophagy is significantly increased in CD4+ T cells from RA patients, and that increased autophagic is also a feature of in vitro activated CD4- T cells, which may contribute to RA pathogenesis. Expand
Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells.
- J. Crider, Gary W. Williams, Colene D. Drace, Parvaneh Katoli, M. Senchyna, N. Sharif
- Biology, Medicine
- Investigative ophthalmology & visual science
- 1 November 2003
Collective data support the presence of a pharmacologically defined, adenylyl cyclase-coupled 5-HT7 receptor in the CEPI-17-CL4 cells that may have relevance to physiological and/or pathologic functions of 5- HT7 receptors in the human cornea. Expand
Cloned human 5‐HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation
- N. Sharif, Colene D. Drace, Gary W. Williams, J. Crider
- Biology, Medicine
- The Journal of pharmacy and pharmacology
- 1 October 2004
The present study provides a detailed pharmacological characterization of the ch‐5‐HT1A receptor using binding and functional assays and correlated well with the pharmacology of endogenous 5‐ HT1A receptors in the rabbit iris‐ciliary body. Expand
The Editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk.
Novel benzodifuran analogs as potent 5-HT2A receptor agonists with ocular hypotensive activity.
- Zixia Feng, S. Mohapatra, +6 authors N. Sharif
- Chemistry, Medicine
- Bioorganic & medicinal chemistry letters
- 1 June 2007
A series of 8-substituted benzodifuran analogs was prepared and evaluated for 5-HT(2A) receptor binding and activation. Several compounds containing ether and ester functionality were found to be… Expand
Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes.
- N. Sharif, Gary W. Williams, J. Crider, Shouxi Xu, T. Davis
- Journal of ocular pharmacology and therapeutics…
- 10 December 2004
DP-class prostaglandins and prostaglandin analogs (collectively, prostaglandins or PGs) such as PGD2, BW245C, ZK110841, and ZK118182, lower intraocular pressure (IOP) in animal models of ocular… Expand